Standard antithymocyte globulin dosing results in poorer outcomes in overexposed patients after ex vivo CD34(+) selected allogeneic hematopoietic cell transplantation Journal Article
| Authors: | Scordo, M.; Bhatt, V.; Hilden, P.; Smith, M.; Thoren, K.; Cho, C.; Shah, G. L.; Maloy, M. A.; Papadopoulos, E. B.; Jakubowski, A. A.; Avecilla, S. T.; O'Reilly, R. J.; Castro-Malaspina, H.; Tamari, R.; Shaffer, B. C.; Boelens, J. J.; Perales, M. A.; Giralt, S. A. |
| Article Title: | Standard antithymocyte globulin dosing results in poorer outcomes in overexposed patients after ex vivo CD34(+) selected allogeneic hematopoietic cell transplantation |
| Abstract: | Antithymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric weight-based dosing of ATG, used to prevent graft rejection in ex vivo CD34-selected allo-HCT, may lead to serious adverse consequences on outcomes in certain patients. We evaluated 304 patients undergoing myeloablative-conditioned ex vivo CD34-selected allo-HCT with HLA-matched donors for the treatment of hematologic malignancies. Patients received rabbit ATG at a dose of 2.5 mg/kg/day i.v. on days -3 and/or -2. An ATG dosing cutoff of 450 mg was used for statistical analyses to assess the relationship between ATG and overall survival (OS). Among all patients, median total ATG dose was 360 mg (range, 130 to 510 mg); 279 (92%) received a total dose of ATG ≤450 mg, and 25 (8%) received a total dose >450 mg. On the first day of ATG administration (day -3), the median absolute lymphocyte count was.0 K/μL. For patients who received a total dose of ATG >450 mg or ≤450 mg, the incidences of acute and late-acute GVHD grade II-IV were statistically similar. At 3 years post-HCT, for patients who received a total dose of ATG >450 mg or ≤450 mg, nonrelapse mortality (NRM) rates were 35% and 18%, respectively (P =.029), disease-free survival (DFS) rates were 37% and 61%, respectively (P =.003), and OS rates were 40% and 67%, respectively (P =.001). Among all patient and HCT characteristics in multivariable analyses, receipt of a total dose of ATG >450 mg was associated with an increased risk of NRM (hazard ratio [HR], 2.9; P =.01), shorter DFS (HR, 2.0; P =.03), and inferior OS (HR, 2.1; P =.01). In summary, the use of weight-based ATG at a time of relative lymphopenia before ex vivo CD34-selected allo-HCT results in overdosing in heavier patients, leading to higher NRM and lower DFS and OS. Further pharmacokinetic investigation in this setting is critical to determining the optimal dosing strategy for ATG. © 2019 American Society for Blood and Marrow Transplantation |
| Keywords: | allogeneic hematopoietic cell transplantation; antithymocyte globulin; ex vivo cd34 selection |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 25 |
| Issue: | 8 |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-08-01 |
| Start Page: | 1526 |
| End Page: | 1535 |
| Language: | English |
| DOI: | 10.1016/j.bbmt.2019.02.021 |
| PUBMED: | 30831208 |
| PROVIDER: | scopus |
| PMCID: | PMC7302932 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 30 August 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work